Video

Episode 2 - Elucidating the Patient's Starting Point in Care

The clinical paradigm for multiple sclerosis (MS) has witnessed an important shift in recent years, and those dynamics can be attributed to the advent of disease-modifying therapies (DMTs), increased awareness, and the conceptual evolution of MS becoming a treatable disease that requires early and effective intervention to better control the damage process caused by MS. Admittedly, while more patients with MS may be entering the health system through specialist referrals and neurologists, improved diagnostic modalities, such as the advances in neurology and neuro-imaging via MRI scan, arguably still does not explain the increased incidence of MS, and unfortunately, diagnosis of the disease is still not occurring early enough.


Related Videos
Molly Dean, MSW, Siftwell
Molly Dean, MSW, Siftwell
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Screenshot of an interview with Shaun McKenzie, MD
Dr Andrew S. Oseran
o Richard Hughes IV, JD, MPH, Epstein Becker Green
Dr Andrew S. Oseran
Dr Andrew S. Oseran
Dr Maria DeYoreo
Screenshot of an interview with Shaun McKenzie, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo